Lupin & Natco Pharma alliance gets approval for Lapatinib Tablets from USFDA

Source

Team Infinities:

Lupin Limited, NSE Symbol: LUPIN, BSE Script Code: 500257, a leading pharmaceutical company alliance with Natco Pharma Limited, NSE Symbol: NATCHOPHARM, BSE Script Code: 524816, a leading pharmaceutical company gets final approval for its Abbreviated New Drug Application(ANDA) for Lapatinib Tablets, 250 mg from United States Food and Drug Administration (USFDA).

Lapatinib Tablets, 250 mg is generic equivalent to Tykerb® Tablets, 250 mg, of Novartis Pharmaceutical Corporation.

Lapatinib Tablets, 250 mg is used for the treatment for cancer, who is suffering  advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2), and who have received prior therapy including an anthracycline, a taxane and trastuzumab and Letrozole for the treatment of postmenopausal women with hormone-receptor positive metastatic breast cancer that overexpresses the HER2 receptor, for whom hormonal therapy is indicated.

As per IQVIA MAT June 2020 Lapatinib Tablets (RLD: Tykerb®) had annual sales of approximately $61 million USD in the U.S.

Add new comment

Comment Editor

  • No HTML tags allowed.